Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptimmune Therapeutics ( (ADAP) ) has shared an announcement.
Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, faced compliance issues with Nasdaq’s listing rules due to its American Depositary Shares trading below the required minimum bid price. On November 1, 2024, the company was notified of non-compliance and given until April 30, 2025, to resolve the issue. Despite an extension granted on May 1, 2025, to October 27, 2025, the company’s shares continued to fall, prompting Nasdaq to issue a delisting notice on August 14, 2025. Adaptimmune intends to request a hearing to present its compliance plan and seek additional time to meet the listing requirements, with its shares remaining on the Nasdaq Capital Market under the symbol ‘ADAP’ during the process.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Underperform.
The overall stock score reflects significant financial challenges, including persistent losses and negative equity, which are the most impactful factors. Technical indicators suggest bearish momentum, and valuation metrics indicate potential undervaluation due to financial instability. Despite positive operational achievements, financial concerns and strategic restructuring weigh heavily on the score.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Average Trading Volume: 17,947,491
Technical Sentiment Signal: Sell
Current Market Cap: $19.8M
For a thorough assessment of ADAP stock, go to TipRanks’ Stock Analysis page.